ANGIOTENSIN II RECEPTOR BLOCKER VALSARTAN AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR ENALAPRIL IN HYPERTENSIVE PATIENTS WITH RENAL TRANSPALANT NEPHROPATHY
- Authors: Maksimov ML1
-
Affiliations:
- Issue: No 5 (2010)
- Pages: 53-56
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245961
- ID: 245961
Cite item
Full Text
Abstract
Aim. Determination of efficacy and safety of enalapril, valsartan and their combination in renal transplant recipients with arterial hypertension.
Methods. 96 renal transplant recipients with systolic blood pressure (BP) >159 mm Hg, diastolic BP >89 mm Hg were included into open label study. Patients were randomized into three groups, in which enalapril (20 mg), valsartan (160 mg) and their combination (enalapril 10 mg and valsartan 80 mg) were used. Changes of BP, albuminuria, plasma renin activity and aldosterone concentration were determined.
Results. All the treatment regimens provided comparable fall in BP, albuminuria and plasma aldosterone concentration. Plasma renin activity elevated, but not significantly. Serious adverse events were nor registered.
Conclusion. In renal transplant recipients enalapril, valsartan and their combination in half doses is effective in lowering blood pressure and albuminuria.
Methods. 96 renal transplant recipients with systolic blood pressure (BP) >159 mm Hg, diastolic BP >89 mm Hg were included into open label study. Patients were randomized into three groups, in which enalapril (20 mg), valsartan (160 mg) and their combination (enalapril 10 mg and valsartan 80 mg) were used. Changes of BP, albuminuria, plasma renin activity and aldosterone concentration were determined.
Results. All the treatment regimens provided comparable fall in BP, albuminuria and plasma aldosterone concentration. Plasma renin activity elevated, but not significantly. Serious adverse events were nor registered.
Conclusion. In renal transplant recipients enalapril, valsartan and their combination in half doses is effective in lowering blood pressure and albuminuria.
References
- Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17
- Ким.И.Г., Стенина И.И., Ильинская И.М., Томилина Н.А. Отдаленные результаты трансплантации почки и факторы риска хронической нефропатии отторжения. Нефрология и диализ. 1999; 1(1): 27-38.
- Мухин Н.А., Фомин В.В. Поражение почек при гипертонической болезни (гипертоническая нефропатия). Чазов Е.И., Чазова И.Е. (ред.) Руководство по артериальной гипертонии. М., MediaMedica, 2005, 265 - 288.
- Мухин Н.А., Фомин В.В., Моисеев С.В. и др. Кардиоренальный синдром при ишемической болезни почек (атеросклеротической реноваскулярной гипертонии. Терапевтический архив. 2008; 8: 30-38.
- Шумаков В.И., Ильинский И.М., Белецкая Л.В. и др. Гистологические и иммуноморфологические исследования хронического отторжения трансплантированных почек. Вестник трансплантологии и исскусственных органов 2000; 3: 30-34
- Томилина Н.А., Балакирев Э.М., Ким И.Г. Отдаленные результаты трансплантации почки. Вестник трансплантологии и искусственных органов. 2001; 3-4: 65-75
- Томилина Н.А., Ким И.Г. Факторы риска позднего прекращения функции трансплантата. Нефрология и диализ. 2000; 4: 260-272.
- Mange K.C., Cizman B., Joffe M., Feldman H.I. Arterial hypertension and renal allograft survival. JAMA. 2000; 283:633-638.
- Mange K.C., Feldman H.I., Joffe M.M. et al. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol, 2004; 15: 187-193
- Wakeel J., Mitwalli A.H., Tarif N. et al. Living unrelated renal transplant: outcome and issues. Saudi J Kidney Dis Transpl. 2000; 11(4): 553-558
- Johnson C.A. Levey A.S., Coresh J. et al. Clinical Practice Guidelines for Chronic Kidney Disease in Adults: Part I. Am Pham Physician. 2004; 70(5): 869-876
- Sanders C.E <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sanders%20CE%20Jr%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Curtis J.J <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Curtis%20JJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl. <javascript:AL_get(this,%20'jour',%20'Kidney%20Int%20Suppl.');> 1995; 52: S43-S47
- Багдасарян А.Р., Столяревич Е.С., Ким И.Г. и др. Влияние эналаприла на скорость прогрессирования хронической трансплантационной нефропатии, Нефрология и диализ 2003; 5(1): 42-47
- Kobori H., Nangaku M., Navar G. et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59(3): 251-287
- Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Invest Drugs 2000; 9: 2593-2600
- Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8
- Wenzel R. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005; 65 Suppl. 2: 29-39
- Burnier M., Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press. 2001; 10 (Suppl. 1): 6-11.
Supplementary files
